CRBP - Corbus Pharmaceuticals Holdings, Inc.
| Previous Close | 7.80 |
| Open | 7.79 |
| Bid | 7.20 x 3100 |
| Ask | 7.50 x 1400 |
| Day's Range | 7.00 - 7.79 |
| 52 Week Range | 4.50 - 9.95 |
| Volume | 1,668,558 |
| Avg. Volume | 1,272,296 |
| Market Cap | 414.744M |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | Aug 14, 2017 - Aug 18, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 23.67 |
- GlobeNewswire•3 days ago
Corbus Pharmaceuticals Presents Data on Impact of Lenabasum on Inflammation of Airway Macrophages from Cystic Fibrosis Lungs at the 2018 North American Cystic Fibrosis Conference
Corbus Pharmaceuticals Holdings, Inc. (CRBP) (“Corbus” or the “Company”), a clinical stage drug development company with the industry’s leading pipeline focused on treating inflammatory and fibrotic diseases by targeting the endocannabinoid system, announced today that it presented new data demonstrating lenabasum’s effect on airway macrophages harvested from human cystic fibrosis lungs at the 2018 North American Cystic Fibrosis Conference being held October 18-20, 2018 in Denver, CO. Lenabasum is the Company's novel, synthetic oral endocannabinoid-mimetic drug, designed to resolve chronic inflammation and halt fibrosis.
- Market Realist•13 days ago
Insys Therapeutics: Performance and Estimates for Q3
Insys Therapeutics (INSY) is a specialty pharmaceuticals company focused on developing cannabinoids and sprays. It reported EPS of -$0.37 on revenues of $23.47 million in the second quarter of 2018.
- Market Realist•16 days ago
Marijuana-Focused Biotech Companies in Q3: Are They Performing?
Biotechnology companies focused on marijuana-based products include GW Pharmaceuticals (GWPH), Cara Therapeutics (CARA), and Insys Therapeutics (INSY). In this series, we’ll look at these stocks and how they performed in the third quarter.
- GlobeNewswire•18 days ago
Corbus Pharmaceuticals Announces Patent Issuance Covering Use of Lenabasum for the Treatment of Fibrotic Diseases Providing Exclusivity to 2034
Company’s vision is to become the leader in the treatment of inflammatory and fibrotic diseases by targeting the endocannabinoid systemIntellectual property around pipeline.
- GlobeNewswire•25 days ago
Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences in October
–Cantor Global Healthcare Conference presentation with live audio webcast on Monday, October 1 st at 2:55 PM ET–. –Leerink Partners Roundtable Series: Rare Disease & Oncology fireside chat and live audio ...
- Motley Fool•last month
Why Corbus Pharmaceuticals Holdings Inc. Tumbled Today
The clinical-stage biotech couldn't hold on to all of the big gains it racked up on Thursday.
- Zacks•last month
Are Options Traders Betting on a Big Move in Corbus Pharmaceuticals (CRBP) Stock?
Investors need to pay close attention to Corbus Pharmaceuticals (CRBP) stock based on the movements in the options market lately.
- TheStreet.com•last month
Can Corbus Pharmaceuticals Hold Its Gains?
Last night on the ever popular Mad Money show on CNBC, our own Jim Cramer sat down with Yuval Cohen for his "Executive Decision" segment. Cohen is the CEO of Corbus Pharmaceuticals Holdings Inc. The share price exploded on the upside Thursday on news the company has struck a deal with Jenrin Discovery to study 600 of their compounds (cannabinoids).
- ACCESSWIRE•last month
Today’s Research Reports on Stocks to Watch: Corbus Pharmaceuticals and Aytu Bioscience
NEW YORK, NY / ACCESSWIRE / September 21, 2018 / Biotech stocks Corbus Pharmaceuticals and Aytu BiosScience were both roaring on Thursday. Shares of Corbus exploded on the news that it has expanded its target indications by adding over 600 compounds that are focused on the endocannabinoid system from Jenrin Discovery. Aytu BioScience didn’t have any news yesterday but earlier in the week provided a clinical trial update.
- Motley Fool•last month
Why Corbus Pharmaceuticals Holdings Is Flying High Today
A licensing deal that boosts its pipeline provided a big catalyst for this clinical-stage biotech.
- TheStreet.com•last month
Cannabis Frenzy Continues With New Age Beverages and Corbus Pharmaceuticals
This stock market has had a number of themes of late, but the one having the most impact is its inconsistency. Thursday morning interest rates have pulled back and bonds have bounced after some tough action Wednesday. While bank stocks are still holding up, the theme I discussed in my opening post about how higher rates could trigger a change in the character of the action has been put on hold.
- GlobeNewswire•last month
Corbus Pharmaceuticals Expands Target Indications by Adding More Than 600 Compounds Focused on the Endocannabinoid System from Jenrin Discovery; Includes CRB-4001 with Planned NIH-Supported Phase 2 Study
Corbus Pharmaceuticals Holdings, Inc. (CRBP) (“Corbus” or the “Company”) announced today that it has licensed the exclusive worldwide rights to develop, manufacture and market drug candidates from more than 600 compounds targeting the endocannabinoid system from Jenrin Discovery LLC (“Jenrin”). The pipeline includes CRB-4001, Jenrin’s 2nd generation, peripherally-restricted, CB1 inverse agonist targeting liver, lung, heart and kidney fibrotic diseases.
- GlobeNewswire•last month
Corbus Pharmaceuticals Receives Orphan Designation for Lenabasum for the Treatment of Dermatomyositis in the European Union
Corbus Pharmaceuticals Holdings, Inc. (CRBP) (“Corbus” or the “Company”), a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases, announced today that the European Commission has granted Orphan Designation in the European Union (“EU”) to lenabasum, its novel, synthetic oral endocannabinoid-mimetic drug, for the treatment of dermatomyositis (“DM”). The Company recently announced that lenabasum was also granted Orphan Drug Designation (“ODD”) for the treatment of DM by the U.S. Food and Drug Administration (“FDA”).
- GlobeNewswire•last month
Corbus Pharmaceuticals Announces Presentation of Three Abstracts and New Lenabasum Data at 2018 ACR Annual Meeting
Norwood, MA, Sept. 14, 2018 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (CRBP) ("Corbus" or the "Company"), a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases, announced today that its abstracts have been selected for presentations at the American College of Rheumatology (“ACR”) 2018 Annual Meeting being held October 19-24, 2018 in Chicago, Illinois. Summarized below are the abstract titles that have been selected for oral or poster presentations. The ACR abstracts are available online at the conference website.
- GlobeNewswire•2 months ago
Detailed Research: Economic Perspectives on Castlight Health, Inc, Noodles, Citi Trends, Corbus Pharmaceuticals, CEVA, and Acxiom — What Drives Growth in Today's Competitive Landscape
NEW YORK, Aug. 29, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Castlight ...
- GlobeNewswire•2 months ago
Corbus Pharmaceuticals to Present at the Annual B. Riley FBR Healthcare Conference
As part of his presentation, Dr. Cohen will discuss the Company's four clinical development programs in diffuse cutaneous systemic sclerosis ("SSc"), cystic fibrosis ("CF"), skin-predominant dermatomyositis ("DM") and systemic lupus erythematosus ("SLE") for lenabasum, its novel, synthetic oral endocannabinoid-mimetic drug that is designed to resolve chronic inflammation and halt fibrosis. Corbus' RESOLVE-1 study, a multicenter, randomized, double-blind Phase 3 study in diffuse cutaneous systemic sclerosis of lenabasum and its Phase 2 study of lenabasum for the treatment of SLE are currently underway.
- GlobeNewswire•2 months ago
Investor Expectations to Drive Momentum within Materialise NV, Southern First Bancshares, Ensco plc, Corbus Pharmaceuticals, TCP Capital, and Horizon Pharma Public — Discovering Underlying Factors of Influence
NEW YORK, Aug. 21, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Materialise ...
- Zacks•2 months ago
Corbus Pharmaceuticals (CRBP) Reports Q2 Loss, Misses Revenue Estimates
Corbus Pharmaceuticals (CRBP) delivered earnings and revenue surprises of -5.00% and -55.05%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•2 months ago
Corbus Pharmaceuticals: 2Q Earnings Snapshot
On a per-share basis, the Norwood, Massachusetts-based company said it had a loss of 21 cents. The drug developer posted revenue of $853,600 in the period. Its adjusted revenue was $854,000. The company's ...
- GlobeNewswire•2 months ago
Corbus Pharmaceuticals Reports 2018 Second Quarter Financial Results and Provides Business Update
Lenabasum has reached Phase 3 clinical stage in two orphan autoimmune indications: systemic sclerosis and dermatomyositis, affecting up to 200,000 patients in the USA, EU and Japan Recent long-term open-label ...
- CNBC Videos•last month
Cramer’s Exec Cut: Bringing the cannabis craze down to ea...
Jim Cramer digs into the substance behind various marijuana plays and advises investors to take caution.
- CNBC Videos•last month
'We're ahead of the pack' in the cannabinoid drug space, ...
Jim Cramer sits down with Yuval Cohen, the CEO of a company that is creating treatments derived from manmade cannabinoids for rare diseases like cystic fibrosis.
- CNBC Videos•last month
Corbus CEO: 'We're ahead of the pack' in the cannabinoid ...
Jim Cramer sits down with Yuval Cohen, the CEO of a company that is creating treatments derived from manmade cannabinoids for rare diseases like cystic fibrosis.
